The breast is a rare site for metastases, and their molecular characteristics have not been studied yet. Intrinsic molecular genetics, cancer characteristics, and breast tissue immune responses in diverse metastases to the breast have not been previously studied. We identified 64 patients with cancers metastatic to the breast: 51 carcinomas and 13 melanomas. Programmed death ligand 1 (PD-L1), steroid receptors, and HER2/neu expressions were evaluated using immunohistochemistry. Gene sequencing, copy number alterations, microsatellite instability, and tumor mutational burden were performed using nextgeneration sequencing platforms. The 3 most common primary sites for metastatic carcinomas were lung (37%), ovary (29%), and fallopian tubes/peritoneum (14%). TP53 mutations were commonly (50%) observed among the carcinoma cases, while other mutations were characteristic for the primary cancers (VHL in renal, BRCA1 in the fallopian tube, and BRAF in melanomas). High tumor mutational burden was detected in 5/14 carcinomas and 3/7 melanomas. Tumor cell PD-L1 expression was detected in 6 carcinomas, but not in any of the melanomas, whereas immune cells' expression of PD-L1 was seen in 17 carcinomas and 6 melanomas. Estrogen receptor status was positive in 13/49 carcinomas including 12 adenocarcinomas originating from the ovary and fallopian tube or peritoneum and 1 duodenal neuroendocrine carcinoma. No carcinoma was HER2/neu positive. Intrinsic genetic characteristics of the metastases to the breast followed the pattern commonly seen in primary tumors. Biomarkers of potential benefit to immune checkpoint inhibition therapy were limited to PD-L1-positive non-small cell lung cancer. No common characteristics of the heterogeneous group of tumor metastases to this organ were identified.
M etastatic cancers to the breast are rare and constitute 1% to 2% of all breast malignancies. 1 When hematologic neoplasms are excluded, the frequency of secondary cancer deposits in the breast is ∼1%. 1 Intramammary metastases are rarely isolated and are typically seen concurrently with metastases to other anatomic sites. 1, 2 A comprehensive review by Koch et al 3 revealed that melanomas are the most common secondary neoplasms in the breast (∼30%) followed by lung, gynecologic, gastrointestinal, and hematologic malignancies.
Comprehensive molecular profiling has become the cornerstone of precision medicine. Apart from the cancers of unknown primary (CUP), most available molecular profiling information that pertains to the targeted cancer treatment originates from the primary tumors. 4 A recently published study by Robinson et al 4 revealed that the most commonly mutated genes in metastatic cancers were TP53, CDKN2A, PTEN, PIK3CA, and RB1. The study also revealed a significant burden of pathogenic germline variants (12. 2% of all tested cases of which 75% were related to DNA repair defects). 4 A study of Kim et al 5 performed on 66 metastatic breast cancer samples using whole-exome, RNA-Seq, and targeted deep sequencing uncovered TP53 and PIK3CA as the most frequent molecular events in breast metastases. A study by Ng et al 6 focusing on synchronous primary breast cancers and their corresponding metastases confirmed a similar mutational portrait. However, metastatic breast cancers were enriched in several unique mutational alterations in genes involved in epithelial-to-mesenchymal transition [eg, SMAD4, TCF7L2, and TCF4 (ITF2)].
Given their rarity, the molecular characteristics of secondary (metastatic) cancers to the breast and their potential impact on therapy decisions are completely unknown. Our comprehensive literature search (all identified studies are summarized in Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/AIMM/A243) revealed no study that specifically explored molecular features of secondary cancers to the breast. In the present study, we reviewed the largest cohort of cancers metastatic to the breast profiled at a single reference center (Caris Life Sciences, Phoenix, AZ) for intrinsic cancer characteristics and biomarkers of immuno-oncologic (I-O) therapies.
MATERIALS AND METHODS

Samples
Cases of metastatic (secondary) cancers to the breast submitted for molecular profiling at Caris Life Sciences between July 2012 and August 2017 were analyzed. The histologic diagnoses including review of the diagnostic immunohistochemical workup performed at the referring pathology laboratories were confirmed in all cases by a board-certified pathologist at Caris Life Sciences. Hematologic malignancies and sarcomas, and melanomas and other cancers affecting the skin of the breast were excluded from the study.
Caris Life Sciences deidentified all the reports and remnant samples provided by the referring laboratories. Given that the remnant tissues from previous samplings with no associated identifiers were used, this research was compliant with 45 CFR 46.101(b). Therefore, the present study was deemed exempt from institutional review board approval, and consent requirements were waived.
Next-generation Sequencing (NGS)
Specimens were profiled using 2 massively parallel NGS (44-gene panel utilizes TruSeq Amplicon panel targeting mutation hotspots in 45 genes; 592-gene panel utilizes SureSelect XT biotinylated RNA probes to capture DNA fragments from the exons of 592 genes (Agilent, Santa Clara, CA), reflecting their availability at the time of testing ( Table 1) . Sequencing of the 44-gene panel used the MiSeq instrument, and, for the 592-gene panel, the NextSeq instrument was used (Illumina, San Diego, CA). [7] [8] [9] Copy number alterations (CNAs) were also explored on samples profiled with the 592-gene NGS panel. CNAs were calculated by comparing the depth of sequencing of genomic loci with a diploid control and the known performance of these genomic loci. Gains ≥ 6 copies were considered amplified. 7, 10 The tumor mutational burden (TMB) was calculated by counting nonsynonymous missense mutations and excluding common germline variants using dbSNP 137 and 1000 genomes. TMB was considered high if ≥ 10 mutations/Mbp were detected, for any cancer type. TMB values were also used to compute a percentile per cancer type. For each of the metastatic cancers to the breast (nonsmall cell lung cancer [NSCLC], small cell lung cancer, melanoma, ovarian carcinoma, bladder carcinoma, breast carcinoma, and CUP), the total number of patients with a certain TMB score was divided by the total number of patients for that cancer cohort, resulting in a percentile score. Table 2 and Figure 1 list the percentiles for 10 representative TMB values, allowing for interconversion between TMB score and percentile. Table 3 lists metastatic cancers' TMB when determined to be "TMB High" with corresponding percentiles relative to TMB = 10 displayed.
Microsatellite instability (MSI) was calculated from the NGS data by direct analysis of short tandem repeat tracts in the target regions of sequenced genes. The count only included alterations that resulted in increases or decreases in the number of repeats; high MSI was defined as ≥ 46 altered microsatellite loci. This threshold was established by comparing NGS with the polymerase chain reaction-based microsatellite fragment analysis results from ∼2100 samples. 7, 8, 11 Immunohistochemistry (IHC) All IHC stains were performed using automated platforms (Benchmark; Ventana Medical Systems and DAKO Autostainer; Agilent, Santa Clara, CA) at a CLIA/CAP/ISO15189/NYSDOH certified clinical laboratory (Caris Life Sciences). Ki-67 (MIB1 antibody) was used to assess the proliferation rate of the neuroendocrine neoplasms (lung and duodenum).
Programmed death ligand 1 (PD-L1) expression was evaluated in the tumor cells (TCs) using SP142 (Ventana; n = 41), 28-8 (Agilent DAKO; for melanoma cases n = 13), and 22c3 clones (Agilent pharmDX DAKO, for NSCLC cases, n = 10) ( Table 1 ). Specimens were considered positive using the SP142 PD-L1 clone if ≥ 5% of TCs exhibited circumferential membranous positivity. [12] [13] [14] The 22c3 positivity in NSCLC was based on established companion diagnostic criteria (Agilent). 28-8 PD-L1 positivity in melanomas was assessed using established complementary diagnostic criteria ( > 1% viable positive cells) for nivolumab treatment in melanoma. We also assessed PD-L1 expression in immune cells (ICs) comprising lymphocytes, macrophages, and dendritic AR indicates androgen receptor; CNA, copy number alteration; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; MSI, microsatellite instability; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; PR, progesterone receptor; TMB, tumor mutational burden. cells. Placental tissue served as a positive control for all PD-L1 antibodies. 7 Androgen receptor (AR; Leica Biosystems), estrogen receptor (ER; Ventana), and progesterone receptor (PR; Ventana) were explored using a ≥ 1% threshold for nuclear positivity for ER and PR 15 and 10% for AR. 10 Only for ovarian/fallopian tube and peritoneal carcinomas, we used the 3+/50% or 2+/75% threshold for ER positivity. Human epidermal growth factor receptor 2 (HER2; Ventana) was considered positive if > 10% cancer cells showed complete, circumferential (3+) expression. 16 
RESULTS
Clinicopathologic Characteristics of the Cohort
We found 64 patients with cancers metastatic to the breast: 51 metastatic carcinomas and 13 melanomas among 4500 breast biopsy specimens that were profiled in the period 2012 to 2017 (frequency ∼1.4%) ( Table 3 ). There were 49 female and 2 male patients (both metastatic renal carcinomas) with a mean age of 57 years (range, 20 to 90 y). The known primary sites of metastatic carcinomas included the following (and they are): lung (n = 19, 30%), ovary (n = 15, 23%), peritoneum/fallopian tube (n = 7, 11%), kidney (n = 4, 6%), bladder (n = 2, 3%), and duodenum and colon (n = 1 each). CUPs were rare (n = 2).
Histologically, 28 of the metastatic carcinomas were adenocarcinomas. Ten cases were neuroendocrine carcinomas (NEC) including 9 from the lung (7 small cell carcinomas (average Ki-67: 55%), 1 large NEC (Ki-67: 90%), 1 atypical carcinoid (Ki-67: 10%), and 1 duodenal NEC (Ki-67: 22%). Two cases were squamous cell carcinomas (both from the lung). Histopathologic evaluation of the 2 CUPs showed squamous carcinoma in 1 and serous-type adenocarcinoma in the other. The remaining 11 cases were of undifferentiated/other types of carcinoma.
Thirteen metastatic melanomas to the breast were encountered in 10 female and 3 male patients (mean age: 54 y, range, 22 to 90 y). Nine cases had no reported/known primary site (melanoma of unknown primary/MUP), 17 while the remaining 4 metastatic melanomas originated from the skin of the head and neck, trunk, and buttock.
Steroid Receptor Profile and HER2 Status in Metastatic Carcinomas
ER was positive in 13/49 tested cases. A vast majority of the ER-positive cases originated from the ovary, fallopian tubes, and/or peritoneum (12 cases); the remaining ER-positive case was metastatic duodenal NEC. PR positivity was observed in 5 cases, originating from the ovary, fallopian tubes, and peritoneum. AR was positive in only 3 cases including 2 ovarian and 1 renal cell carcinoma. None of the tested cases (n = 45) exhibited HER2 positivity. Both CUP cases were negative for all 3 steroid receptors and HER2. None of the cases harbored mutations in the estrogen receptor gene (ESR1) or the ERBB2 (HER2) gene. 
I-O Biomarkers in Metastatic Carcinomas
PD-L1 Status
PD-L1 expression on TCs was present in n = 6/51 cases (12%). PD-L1 TC-positive cases included 4 NSCLC (2 adenocarcinomas, 1 squamous cell carcinoma, and 1 NSCLC not otherwise specified, respectively), 1 bladder carcinoma, and 1 CUP case with squamous differentiation. Of note, 2 cases (lung adenocarcinoma and a CUP with squamous differentiation) exhibited high PD-L1 positivity (80% positivity).
The expression of PD-L1 in ICs was observed in n = 17/51 cases. The positive cases included metastatic lung (n = 7, 3 of which were NEC), peritoneal (n = 3), bladder, ovarian and fallopian tube (n = 2 each), and colorectal carcinoma (n = 1). Only 3 cases demonstrated moderate to strong IC PD-L1 expression (30% to 50% positive ICs) (1 case each of bladder, ovarian, and fallopian tube carcinoma). Of note, 3 cases (2 NSCLC and 1 bladder carcinoma) had PD-L1 positivity in both cancer and ICs. None of the CUP cases had PD-L1 expression in ICs.
TMB and MSI Status in Metastatic Carcinomas and Primary Breast Cancers
TMB results were available for n = 14 metastatic carcinomas; the average TMB was 9.6 mutations/Mbp. High TMB was observed in 5 cases: three lung carcinomas, 1 ovarian, and 1 CUP case ( Table 3 ). The highest TMB was observed in the CUP case with squamous differentiation (29 mutations/Mbp). This case also exhibited a diffuse (80%) PD-L1 expression.
MSI status was available for n = 14 metastatic carcinomas; all were microsatellite stable.
Mutational Profile and CNAs of Metastatic Carcinomas
The mutational profile of the cohort is summarized in Table 4 . TP53 mutation was the most common (50%) across all the histologies and lineages. Four cases with KRAS mutations were observed: Two mutations were seen in NSCLCs, 1 in peritoneal adenocarcinoma and in 1 CUP case (adenocarcinoma), respectively. Similarly, 4 lung-primary cases had RB1 gene mutations (2 small cell lung cancer, 1 squamous, and 1 not otherwise specified, respectively). Three loss-of-function mutations in PTEN were detected (2 lung neuroendocrine and 1 lung adenocarcinoma). One case each of lung and ovarian adenocarcinoma carried pathogenic BRAF gene mutations. Similarly, 2 NRAS gene mutations were detected in 1 ovarian and colorectal adenocarcinoma, respectively. Two PIK3CA gene mutations were present in 1 renal and bladder carcinoma case. The first CUP presented with squamous differentiation harbored mutations in TP53, KDM6A, and TSC2 genes along with the amplification of the NFIB gene. The second CUP case (adenocarcinoma histology) harbored mutations in both KRAS and STK11 genes.
Some of the detected mutations were lineage-characteristic: 2 VHL mutations in renal clear cell carcinomas and 1 SMARCB1 mutation in a renal medullary carcinoma case; one BRCA1 mutation was detected in a fallopian tube carcinoma. The remaining ovarian and peritoneal carcinomas (n = 7) did not have BRCA mutations. Neuroendocrine lung carcinomas (n = 8) harbored TP53 and RB1 gene mutations (n = 2 each). Other mutations (AKT1, APC, ARID1A, ARID2, FANCC, FBXW7, and TSC2) were rare and affected single cases. Only 1, unusual EGFR gene mutation (p.R776C) was detected in a case of pulmonary adenocarcinoma. CNAs were available for 13 carcinomas. Gains ( ≥ 6 copies) were observed in 12 genes including ADGRA2 (n = 2 cases), AKT2 (n = 2 cases), CCNDA, CCNE, FGF, FGF3, FGF4, FGFR, MYB, NFIB, NSD3, and ZNF7 (n = 1 case each). Only 2 carcinomas harbored > 1 CNA: ovarian serous adenocarcinoma (6 genes: ADGRA2, CCNDA, FGF, FGF3, and FGF4) and lung squamous cell carcinoma (4 genes: ADGRA2, AKT2, FGFR, and NSD3).
The Predictive Biomarkers in Metastatic Melanomas
PD-L1 expression on melanoma TCs ( > 1%) was not observed in any of the tested cases (all TC negative). However, PD-L1-positive ICs were detected in half of the cases (n = 6/12).
High TMB was detected in 3/5 metastatic melanomas, including 2 MUP cases, with the average TMB of 9.6 mutations/Mbp. All tested cases were microsatellite stable.
BRAF mutations were detected in 8/12 metastatic melanomas, including 6/8 MUP cases. NRAS mutation was present in only 1 case (MUP). None of the melanoma cases harbored GNAS gene mutations, although 1 case harbored concurrent mutations in GNA11 and SF3B1. No other detected molecular alterations were recurrent.
CNAs were available for 4 melanoma cases. Only 1 case (skin melanoma) harbored amplifications of the CYP2D6 and EP3 genes.
DISCUSSION
Secondary (metastatic) cancers to the breast are rare and contribute to ∼1% of all breast malignancies. 1 Our results on the frequency and types of secondary mammary malignancies affecting the breast are in line with previously published data 1,3 (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/AIMM/ A243). CUPs were rare (only 2 were present in our series), whereas MUP site was more common. [17] [18] [19] [20] [21] Our study explored the biomarkers of targeted and I-O therapy in this unique group of breast malignancies.
Among the metastatic carcinomas, a vast majority (80%) originated from lung and reproductive tract/peritoneum. Half of the metastatic lung cancers were NEC. These cancers may be clinically and histologically confused for the primary mammary carcinomas with neuroendocrine differentiation. 1 In contrast to the NEC of the breast, 10 metastatic NEC from the lung were uniformly negative for steroid receptors ER, PR, and AR. In addition, these cancers lacked TC PD-L1 expression and exhibited low TMB, as previously reported. 22, 23 However, we confirm low (1% to 10%) IC PD-L1 in a proportion of the metastatic pulmonary NECs, as reported by several studies. 23, 24 Metastatic gynecologic/peritoneal carcinomas may also be confused for the primary mammary malignancies, not only morphologically but immunohistochemically, due to the frequent expression of steroid receptors, as confirmed in our study. None of these cases harbored mutations in the ESR1 gene (encodes ER), which may be seen in ∼20% of ER-positive breast cancers, particularly in a metastatic setting. [25] [26] [27] In addition, HER2 protein expression was consistently negative among the metastatic cancers to the breast, which is in contrast to the primary breast cancers (frequency 15% to 20%). HER2 alterations (amplification and/or mutation) were also absent. HER2 mutations have been increasingly recognized across the various cancers including breast (∼2% to 3%), colorectal (∼1.5%), gastric/gastroesophageal junction (∼1.5%), genitourinary (∼1%), gynecologic (∼1%), lung (1%), and CUPs (∼1%). [28] [29] [30] [31] [32] These mutations are associated with the acquired resistance to HER2-targeted therapies. 33 Our data on I-O profile of metastatic gynecologic/ peritoneal carcinomas are in line with the previously published data on their metastases to nonbreast sites. 34, 35 Thus, metastatic ovarian and fallopian tube/peritoneal carcinomas were frequently enriched with PD-L1-positive tumor-infiltrating lymphocytes, and a subset of these harbored a high TMB. Such molecular alterations make these cancers potentially amenable for the trials with immune checkpoint inhibitors.
Three generations of EGFR tyrosine kinase inhibitors have been used for the treatment of NSCLC harboring EGFR gene mutations. 36, 37 EGFR mutations have been described in 14% to 23% NSCLCs among the North American population. 38 Activating EGFR gene mutations are frequently detectable in metastatic NSCLCs. [39] [40] [41] [42] A recent report of Ota et al 43 confirmed the presence of an activating EGFR gene mutation in a case of metastatic pulmonary adenocarcinoma to the breast. In addition, the author's literature survey revealed EGFR mutations in 4/4 tested intramammary metastases of pulmonary adenocarcinomas. 43 In our study, a rare pathogenic EGFR mutation was detected in 1 case (pulmonary adenocarcinoma). The detected mutation (p. R776C) affects the protein kinase domain of the EGFR, resulting in its constitutive phosphorylation. 44, 45 The presence of such a mutation may also have therapeutic implications given that it may decrease the sensitivity to gefitinib and increase the sensitivity to erlotinib and AEE788. 46 The remaining metastatic NSCLCs in our study were devoid of EGFR gene alterations; hence, these cancers may not be suitable for treatment with EGFR tyrosine kinase inhibitors. We had 2 CUP cases in our cohort, 1 with squamous and another with adenocarcinoma differentiation. The case presenting with squamous differentiation had a high TMB and high PD-L1 expression, making the patient potentially amenable to the treatment with immune checkpoint inhibitors. 7 The other case of CUP harbored concurrent KRAS (p.G12V) and STK11 (p. D194N) gene mutations. Germline STK mutations have been described in patients with Peutz-Jeghers syndrome (OMIM # 175200), whereas somatic STK11 mutations have been reported in a wide spectrum of malignancies including lung, cervical, pancreatic, testicular, and other cancers. 47, 48 In the context of activating KRAS mutations, mutations leading to a loss of STK11 function have been associated with decreased response to immune checkpoint inhibitors. 49 The molecular profile of metastatic melanomas to the breast (PD-L1 and TMB status) are concordant with the previous studies on cutaneous melanoma, including MUP cases. [50] [51] [52] [53] [54] It is well known that BRAF-mutant melanomas are prone to exhibit more aggressive biological behavior than BRAF wild-type melanomas. 55 We found pathogenic BRAF mutations in two thirds of metastatic melanomas, which is comparable to previous studies (∼50%). [55] [56] [57] One case harbored concurrent mutations in GNA11 (p. Q209L) and SF3B1 (p. R625C). Although these mutations are mostly associated with uveal melanoma, they have also been reported in skin and mucosal melanomas. 58, 59 In an analysis of publically available genomic databases (TCGA), no GNA11 Q209 mutations were detected outside of melanoma. SF3B1 R625 mutations were enriched in nonuveal melanomas compared with other "hotspot" mutations; however, SF3B1 mutations in previously determined "hotspots" were also identified in primary breast carcinoma (1.1% of samples with the highest incidence of p.K700E). Melanomas of cutaneous origin that harbor these mutations have been associated with lower TMB and a lack of response to immunotherapies. 60 This is, however, not fully consistent with our findings given that the specimen had a high TMB (13 mutations/Mbp), although no PD-L1 expression on either TC or IC components was observed.
In a small proportion of metastatic cancers to the breast, we detected a lineage-characteristic mutation that may improve the diagnosis (eg, VHL in renal clear cell carcinomas, SMARCB1 in renal medullary carcinomas) and/or have therapeutic implications (BRCA1 and BRAF). Thus, BRCA1 mutations in fallopian tube carcinomas and BRAF mutations in melanomas may guide targeted treatments with poly (ADP-ribose) polymerase, and BRAF and MEK inhibitors.
In conclusion, we confirm the rarity of secondary cancers to the breast (1.4% of all breast biopsies with a malignancy). Their histotype distribution is in line with previous studies. 1, 3 Metastatic cancers to the breast shared similar molecular profile to their primary counterparts. The study also revealed a marked heterogeneity in terms of biomarkers of potential benefit to I-O and targeted therapies, necessitating individual patient profiling. The clinical impact of the targetable biomarkers in secondary cancers to the breast has to be determined.
